Abstract 2094P
Background
Dexamethasone is one of the key antiemetic agents and is widely used even now. However, dexamethasone has been associated with a number of adverse reactions even after short-term administration. Therefore, the development of steroid-free antiemetic regimen is an important issue to be considered. Thus, the purpose of this study was to investigate the efficacy and safety of palonosetron, aprepitant, and olanzapine in a multi-institutional phase II study.
Methods
Chemotherapy-naive patients scheduled to receive for highly emetogenic chemotherapy in breast cancer were enrolled and evaluated the occurrence of chemotherapy-induced nausea and vomiting during 120 hours after chemotherapy. The primary endpoint of the study was total control (TC) in the overall phase. Key secondary endpoint was complete response (CR), which was assessed in the acute, delayed, and overall phase, respectively. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events.
Results
Eighty-nine patients were enrolled from 8 centers in Japan, of which 76 were evaluable for analyses. The percentage of patients achieved TC during the overall phase was 17.1% (95% confidence interval [CI] 0.094–0.275; p = 0.275). CR was achieved in 43.4% (95% CI 0.321–0.553; p = 0.726), 53.9% (95% CI 0.421–0.655), and 63.2% (95% CI 0.513–0.739) of patients during the overall, acute, and delayed phases, respectively
Conclusions
The primary endpoint was below the threshold and we could not find any benefit in the dexamethasone-free regimen. The CR rate was also examined as one of the secondary endpoints, with similar results. Although dexamethasone is considered to have side effect concerns, its effect on CINV cannot be ignored, suggesting that easy complete omission should be avoided.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Tsuji: Financial Interests, Personal, Invited Speaker: Taiho Phamaceutical Co., Ltd., Kyowa Kirin Co., Ltd. K. koizumi: Financial Interests, Personal, Invited Speaker: Pfizer, Chugai Pharmaceutical. K. Suzuki: Financial Interests, Personal and Institutional, Invited Speaker: Taiho, Nipro. All other authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06